Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

 
News
 
 
Language
 
Friday, November 21. 2014
 
Basel, Switzerland, November 21, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA) announced a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the New Drug Application (NDA) for the investigational antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partner Astellas Pharma Inc. The meeting is scheduled for Thursday, January 22, 2015.
 
more...
 
Wednesday, November 19. 2014
 
  • BAL101553 anti-cancer activity in treatment-refractory cancer models, alone and in combination with radiotherapy, presented at EORTC-NCI-AACR Symposium*
  • BAL101553 has anti-tumor activity when administered i.v. or orally in
    in-vivo models of human cancer refractory to taxanes and epothilones
  • Combination of BAL101553 with radiotherapy led to profound tumor growth delay
 
more...
 
Monday, November 03. 2014
 
Basel, Switzerland, November 3, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis/candidemia, a potentially life-threatening infection caused by Candida yeasts. Isavuconazole has previously been granted orphan drug status in the European Union and the U.S. for the treatment of invasive aspergillosis and mucormycosis.
 
more...
 
Thursday, October 16. 2014
 
Basel, Switzerland, October 16, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its partner Astellas Pharma Inc. has filed an amendment to the phase 3 ACTIVE study protocol with the relevant health authorities and ethics committees. The study assesses the investigational antifungal isavuconazole in the treatment of candidemia and other invasive Candida infections.
 
more...
 
Info
 
 
 

IDSA
Infectious Diseases
Society of America
Doctorfungus